Brilacidin antiviral and anti-inflammatory data has been accepted for a scientific poster presentation at the 2022 Chemical and Biological Defense Science & Technology Conference (CBD S&T), December 6-9, 2022, based on research conducted at George Mason University’s Center for Infectious Disease Research.

The CBD S&T is sponsored by the U.S. government’s Defense Threat Reduction Agency’s (DTRA) and provides an interactive forum for chemical and biological defense community members from around the world to discuss pressing chem-bio threats.

Data generated in alphaviruses and bunyaviruses showed Brilacidin possesses antiviral and anti-inflammatory properties, reinforcing its potential as a broad-spectrum antiviral.

The conference abstract can be accessed here.